← Eichor
Condition: Pirtobrutinib Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Pirtobrutinib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
Phase 2 · 2 location(s) · University of Utah · NCT06390956A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Phase 1/Phase 2 · 45 location(s) · Eli Lilly and Company · NCT06721013A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 4 · 50 location(s) · Eli Lilly and Company · NCT07218341Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
Phase 2 · 16 location(s) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ó · NCT07285590Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
Phase 2 · 3 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06553872Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chroni
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05536349Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Tri
Phase 2 · 1 location(s) · University of Washington · NCT06948786Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
Phase 2 · 3 location(s) · Peter MacCallum Cancer Centre, Australia · NCT06812715Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07416890Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Rec
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06967610Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transfor
Phase 2 · 5 location(s) · Christine Ryan · NCT06043674Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 · 3 location(s) · University of California, San Francisco · NCT06252675Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
NA · 1 location(s) · Northwell Health · NCT05643235A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymph
Phase 3 · 143 location(s) · Loxo Oncology, Inc. · NCT05254743A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sint
Phase 2 · 4 location(s) · Tongji Hospital · NCT07350850Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05529069ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Phase 3 · 4 location(s) · Newave Pharmaceutical Inc · NCT07342478Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymph
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06263491R-PMDT Regimen in Newly Diagnosed PCNSL
Phase 2 · 1 location(s) · Zou Dehui · NCT07604987A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocy
Phase 4 · 36 location(s) · Eli Lilly and Company · NCT06876662A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Ch
Phase 3 · 197 location(s) · BeOne Medicines · NCT06973187A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocy
Phase 2 · 131 location(s) · Loxo Oncology, Inc. · NCT06588478A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
Phase 2 · 2 location(s) · Australasian Leukaemia and Lymphoma Group · NCT05833763LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Phase 1 · 1 location(s) · Medical College of Wisconsin · NCT05990465Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Phase 2 · 1 location(s) · Kerry Rogers · NCT06466122A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Phase 4 · 38 location(s) · Eli Lilly and Company · NCT06876649Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Phase 2 · 4 location(s) · Inhye Ahn · NCT06333262Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07255963Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
Phase 2 · 1 location(s) · Jennifer Woyach · NCT07685717Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
EARLY_Phase 1 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT07428707
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.